NeuCyte

Executive Summary

NeuCyte is a privately held, early-stage biotechnology company headquartered in Sunnyvale, California, singularly focused on the discovery and development of small-molecule therapeutics for neurological diseases. Founded in 2015, the company leverages proprietary cell-based target-identification and drug-discovery platforms to streamline the often protracted and costly process of developing central nervous system (CNS) therapies. By utilizing human cell-based models, NeuCyte aims to improve translational accuracy and identify novel drug candidates with higher predictivity for clinical success. The company's platform-centric approach positions it to address a broad range of neurological indications, though specific pipeline programs have not been disclosed publicly. As an early-stage entity with no disclosed financing rounds or clinical-stage assets, NeuCyte remains in a discovery and preclinical phase, relying on its technology to attract partnerships or funding to advance its programs toward the clinic.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round60% success
• H1 2027Lead Program Preclinical Proof-of-Concept Data40% success
• 2026Research Collaboration or Licensing Deal50% success